|
|
| (9 intermediate revisions not shown.) |
| Line 1: |
Line 1: |
| - | [[Image:1pmq.gif|left|200px]] | + | #REDIRECT [[4z9l]] This PDB entry is obsolete and replaced by 4z9l |
| - | | + | |
| - | {{Structure
| + | |
| - | |PDB= 1pmq |SIZE=350|CAPTION= <scene name='initialview01'>1pmq</scene>, resolution 2.2Å
| + | |
| - | |SITE=
| + | |
| - | |LIGAND= <scene name='pdbligand=880:CYCLOHEXYL-{4-[5-(3,4-DICHLOROPHENYL)-2-PIPERIDIN-4-YL-3-PROPYL-3H-IMIDAZOL-4-YL]-PYRIMIDIN-2-YL}AMINE'>880</scene>, <scene name='pdbligand=ANP:PHOSPHOAMINOPHOSPHONIC+ACID-ADENYLATE+ESTER'>ANP</scene>
| + | |
| - | |ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase Mitogen-activated protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.24 2.7.11.24] </span>
| + | |
| - | |GENE= MK10_HUMAN ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])
| + | |
| - | |DOMAIN=
| + | |
| - | |RELATEDENTRY=[[1pmn|1PMN]], [[1pmu|1PMU]], [[1pmv|1PMV]]
| + | |
| - | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1pmq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1pmq OCA], [http://www.ebi.ac.uk/pdbsum/1pmq PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1pmq RCSB]</span>
| + | |
| - | }}
| + | |
| - | | + | |
| - | '''The structure of JNK3 in complex with an imidazole-pyrimidine inhibitor'''
| + | |
| - | | + | |
| - | | + | |
| - | ==Overview==
| + | |
| - | The c-Jun terminal kinases (JNKs) are members of the mitogen-activated protein (MAP) kinase family and regulate signal transduction in response to environmental stress. Activation of JNK3, a neuronal-specific isoform, has been associated with neurological damage, and as such, JNK3 may represent an attractive target for the treatment of neurological disorders. The MAP kinases share between 50% and 80% sequence identity. In order to obtain efficacious and safe compounds, it is necessary to address the issues of potency and selectivity. We report here four crystal structures of JNK3 in complex with three different classes of inhibitors. These structures provide a clear picture of the interactions that each class of compound made with the kinase. Knowledge of the atomic interactions involved in these diverse binding modes provides a platform for structure-guided modification of these compounds, or the de novo design of novel inhibitors that could satisfy the need for potency and selectivity.
| + | |
| - | | + | |
| - | ==About this Structure==
| + | |
| - | 1PMQ is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1PMQ OCA].
| + | |
| - | | + | |
| - | ==Reference==
| + | |
| - | The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity., Scapin G, Patel SB, Lisnock J, Becker JW, LoGrasso PV, Chem Biol. 2003 Aug;10(8):705-12. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12954329 12954329]
| + | |
| - | [[Category: Homo sapiens]]
| + | |
| - | [[Category: Mitogen-activated protein kinase]]
| + | |
| - | [[Category: Single protein]]
| + | |
| - | [[Category: Becker, J W.]]
| + | |
| - | [[Category: Lisnock, J.]]
| + | |
| - | [[Category: LoGrasso, P V.]]
| + | |
| - | [[Category: Patel, S B.]]
| + | |
| - | [[Category: Scapin, G.]]
| + | |
| - | [[Category: apoptosis]]
| + | |
| - | [[Category: inhibition]]
| + | |
| - | [[Category: map kinase]]
| + | |
| - | | + | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 23:01:42 2008''
| + | |
